Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.

Clin Cancer Res · 2022 · PMC9365365 · PMID 35091441

Europe PMC DOI

hedged sentence

0.1614

closest p · 3.2× alpha

0.1614

boldest claim

The sentences

did not reach statistical significanceP = 0.1614not close (p > 0.1)

In the chemotherapy group, PFS was shorter in patients with TP53 mutations than in those without; however, this did not reach statistical significance [HR (95% CI) = 1.439 (0.859–2.411); P = 0.1614].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.